Drug Profile
Formoterol dry-powder inhalation - AstraZeneca
Alternative Names: Eformoterol dry-powder inhalation - AstraZeneca; Formoterol fumarate dry-powder inhalation - AstraZeneca; Formoterol Turbuhaler; Oxez Turbuhaler; Oxeze Turbuhaler; Oxis; Oxis TurbuhalerLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease; Exercise-induced asthma
Most Recent Events
- 15 Apr 2021 No development reported - Phase-II for Chronic obstructive pulmonary disease in USA (Inhalation)
- 01 Dec 2016 AstraZeneca completes a phase II trial for Chronic obstructive pulmonary disease in USA (Inhalation) (NCT02796651)
- 01 Jun 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)